A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

Climent, Miguel Ángel; Font, Albert; Durán, Ignacio; Puente, Javier; Mendez-Vidal, María José; Sáez, María Isabel Corbí; Lobera, Carmen Santander; Arija, José Ángel Arranz; González-del-Alba, Aranzazu; Sánchez-Hernández, Alfredo; Fita, María José Juan; Esteban, Emilio; Alonso‐Gordoa, Teresa; González, B. Mellado; Maroto, Pablo; Lázaro-Quintela, Martín; Cassinello-Espinosa, Javier; Pérez-Valderrama, Begoña; Garcias, Carmen; Castellano, Daniel

doi:10.1016/j.ejca.2022.08.002

Cited by 8 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ABIDO-SOGUG trial randomized 94 men with mCRPC progressing on abiraterone/prednisone to ongoing abiraterone plus docetaxel and 10 mg prednisone daily versus docetaxel and prednisone alone. There was no difference in 12-month PFS or OS between the two groups, and interestingly, Grade ≥ 3 neutropenia was far more common in the combination arm than with docetaxel alone at 59.6% vs. 27.7% [25 ▪ ]. The prospective double blind phase III PRESIDE trial randomized 271 men with mCRPC progressing on enzalutamide to docetaxel with 10 mg prednisone daily plus enzalutamide or placebo.…”

Section: Tweaking Existing Therapies and Novel Interventions For Refr...mentioning

confidence: 99%

Highlighting recent progress in the treatment of men with advanced prostate cancer

Gourdin

2024

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review This review is designed to highlight recent research efforts to optimize treatment strategies in men with advanced prostate cancer. Recent findings Recent research analyses have suggested an overall survival advantage to treating some men with newly identified metastatic prostate cancer with a “triplet” of androgen deprivation therapy, docetaxel, and an androgen receptor axis-targeted agent (ARAT), but further work remains to refine which men need this aggressive of a treatment approach. Randomized trials have led to the approval of poly(ADP-ribose) polymerase inhibitor/ARAT agent combinations for some men with metastatic castration resistant prostate cancer, but the applicability of this approach to the growing number of men receiving combinations of systemic therapy in the castration-sensitive setting is unclear. Trials to refine use of prostate-specific membrane antigen (PSMA)-directed radiopharmaceuticals are ongoing, while novel treatment approaches targeting mechanisms driving advanced prostate cancer continue to be explored. Summary Ongoing research focuses on refining the best combination and sequence of treatments for men with advanced prostate cancer. Future questions remain about use of existing therapies, and novel treatment approaches need to be developed.

show abstract

Section: Tweaking Existing Therapies and Novel Interventions For Refr...mentioning

confidence: 99%

Highlighting recent progress in the treatment of men with advanced prostate cancer

Gourdin

2024

Current Opinion in Oncology

View full text Add to dashboard Cite

show abstract

Assessment of the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Almeida,

García Megías,

Etchebehere

et al. 2024

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis

Xiong,

Zhang,

Zheng

et al. 2024

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial

Cited by 8 publications

References 17 publications

Highlighting recent progress in the treatment of men with advanced prostate cancer

Highlighting recent progress in the treatment of men with advanced prostate cancer

Assessment of the therapeutic efficacy of [177Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis

Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis

Contact Info

Product

Resources

About